G92.03
Immune effector cell-associated neurotoxicity syndrome, grade 3
Clinical Classification Guidelines
Inclusion Terms
- ICANS, grade 3
Medical Intelligence & Overview
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological complication that can occur after certain cancer treatments, particularly those involving immune cells like CAR T-cell therapy. Grade 3 indicates a severe level of neurotoxicity. This condition warrants prompt medical attention to manage symptoms and prevent further health deterioration.
Causes & Symptoms
Clinical Causes: Administration of immune effector cell therapies, such as CAR T-cell therapy Overactivation of the immune system leading to neuroinflammation High tumor burden prior to treatment Pre-existing neurological conditions that may predispose to neurotoxicity Older age and other patient-specific factors
Key Symptoms: Severe confusion or disorientation Altered mental status, including agitation or hallucinations Difficulty speaking or understanding speech Seizures Weakness or numbness in limbs Incoordination or tremors High fever and elevated blood pressure Signs of increased intracranial pressure
Diagnostic & Treatment
Diagnosis Path: Neurological assessments to evaluate mental status, cranial nerves, motor and sensory skills Blood tests to rule out infections or metabolic causes Imaging studies like MRI or CT scans to identify brain swelling or other abnormalities Lumbar puncture to analyze cerebrospinal fluid if needed Monitoring of neurological symptoms over time
Treatment Protocols: Corticosteroids to reduce brain inflammation Anticonvulsants if seizures occur Supportive care, including oxygen therapy and fluid management Close neurological monitoring in a specialized care setting Adjustments to the underlying immune therapy, if appropriate
Clinical Advice & FAQs
Billing Guidance
Is G92.03 a billable ICD-10 code?
Yes, G92.03 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.03?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome, grade 3 and any associated comorbidities for accurate reporting.
Cite this Clinical Reference